News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Innova Biosciences Awarded EU Grant To Develop Cancer Biomarker Discovery Platform



2/17/2009 2:14:47 PM

Innova Biosciences Ltd (Cambridge, UK), a leader in the field of bioconjugation, has been awarded €455,000 of a €3,000,000 European grant. Through the PROACTIVE consortium along with Olink, Copenhagen University, Fujirebio Diagnostics AB, Uppsala University, and Integromics S.L., a unique high throughput plasma screening platform will be developed for the discovery of biomarkers of early stage cancer.

Innova Biosciences has had enormous success with its range of Lightning-Link™ bioconjugation products, which provide a uniquely simple method for joining biomolecules, a process carried out in thousands of research laboratories worldwide. Innova Biosciences’ participation in the PROACTIVE consortium to develop immunodiagnostics reagents will help cement the company’s position as a world leader in bioconjugation technology.

Commenting on the EU grant Dr Nick Gee, CEO of Innova Biosciences said “We are delighted to be granted such a prestigious award which recognises Innova’s proprietary knowledge and expertise. Participating in the development of a new immunodiagnostic platform that will facilitate early stage cancer detection is an exciting application of our technology, which will directly benefit human health.”

About the company: Innova Biosciences is a growing, dynamic business, based in Cambridge, UK. At the core of Innova’s business is the Lightning-Link™, an innovative technology that simplifies production of bioconjugates for use in R&D applications, drug discovery and diagnostics. The expanding Lightning-Link™ portfolio currently consists of 43 products and is sold to research laboratories in over 30 countries around the world.


Read at BioSpace.com


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES